ATE333448T1 - Arylthiazolidinedione und aryloxa zolidinedion- derivate - Google Patents

Arylthiazolidinedione und aryloxa zolidinedion- derivate

Info

Publication number
ATE333448T1
ATE333448T1 AT00944694T AT00944694T ATE333448T1 AT E333448 T1 ATE333448 T1 AT E333448T1 AT 00944694 T AT00944694 T AT 00944694T AT 00944694 T AT00944694 T AT 00944694T AT E333448 T1 ATE333448 T1 AT E333448T1
Authority
AT
Austria
Prior art keywords
aryloxa
zolidinedione
arylthiazolidinedione
derivatives
aryl
Prior art date
Application number
AT00944694T
Other languages
English (en)
Inventor
Soumya P Sahoo
Conrad Santini
Julia K Boueres
James V Heck
Edward Metzger
Victoria K Lombardo
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE333448T1 publication Critical patent/ATE333448T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AT00944694T 1999-06-18 2000-06-16 Arylthiazolidinedione und aryloxa zolidinedion- derivate ATE333448T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13995399P 1999-06-18 1999-06-18

Publications (1)

Publication Number Publication Date
ATE333448T1 true ATE333448T1 (de) 2006-08-15

Family

ID=22489062

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00944694T ATE333448T1 (de) 1999-06-18 2000-06-16 Arylthiazolidinedione und aryloxa zolidinedion- derivate

Country Status (9)

Country Link
US (1) US6399640B1 (de)
EP (1) EP1194146B1 (de)
JP (1) JP2003502369A (de)
AT (1) ATE333448T1 (de)
AU (1) AU773505B2 (de)
CA (1) CA2376919C (de)
DE (1) DE60029446T2 (de)
ES (1) ES2265952T3 (de)
WO (1) WO2000078312A1 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078314A1 (en) * 1999-06-18 2000-12-28 Merck & Co., Inc. Process for making arylthiazolidinedione derivatives
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
AU2001298065A1 (en) * 2001-01-12 2003-09-02 Abbott Laboratories Process for the preparation of matrix metalloproteinase inhibitors
SI1413331T1 (sl) 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
EP1911462A3 (de) 2001-01-26 2011-11-30 Schering Corporation Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
JP4711600B2 (ja) 2001-01-26 2011-06-29 シェーリング コーポレイション シトステロール血症の処置のための置換アゼチジノン化合物の使用
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CA2457976A1 (en) 2001-08-22 2003-03-06 Aventis Pharma Deutschland Gmbh Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
US20040198774A1 (en) * 2001-08-23 2004-10-07 Shinichi Ishii Preventive and/or remedial agent for disease attributable to arteriosclerotic activity
US7399777B2 (en) 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
US6884812B2 (en) 2001-08-31 2005-04-26 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
JP4436129B2 (ja) 2001-08-31 2010-03-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ジアリールシクロアルキル誘導体、その製造法及びｐｐａｒ−活性剤としてのその使用
US6869975B2 (en) 2001-09-14 2005-03-22 Tularik Inc. Linked biaryl compounds
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ITRM20020016A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
US7223796B2 (en) 2002-04-11 2007-05-29 Sanofi-Aventis Deutschland Gmbh Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
US7078404B2 (en) 2002-04-11 2006-07-18 Sanofi-Aventis Deutschland Gmbh Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use
US7049341B2 (en) 2002-06-07 2006-05-23 Aventis Pharma Deutschland Gmbh N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7262220B2 (en) 2002-07-11 2007-08-28 Sanofi-Aventis Deutschland Gmbh Urea- and urethane-substituted acylureas, process for their preparation and their use
DE50312261D1 (de) 2002-07-12 2010-02-04 Sanofi Aventis Deutschland Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US20040157922A1 (en) 2002-10-04 2004-08-12 Aventis Pharma Deutschland Gmbh Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
CA2504878A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US20040242583A1 (en) * 2003-01-20 2004-12-02 Aventis Pharma Deutschland Gmbh Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7196114B2 (en) 2003-02-17 2007-03-27 Sanofi-Aventis Deutschland Gmbh Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
CN100439361C (zh) 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7501440B2 (en) 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
WO2004108126A1 (en) * 2003-06-06 2004-12-16 Snowden Pharmaceuticals, Llc Fibric acid derivatives for the treatment of irritable bowel syndrome
CA2531418A1 (en) * 2003-07-08 2005-01-20 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
US7008957B2 (en) 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7094800B2 (en) 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
US7094794B2 (en) 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (de) 2003-08-01 2005-02-03 Aventis Pharma Deutschland Gmbh Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
SI1667964T1 (sl) * 2003-09-19 2009-12-31 Janssen Pharmaceutica Nv 4-((fenoksialkil)tio)-fenoksiocetne kisline in analogi
BRPI0414534B8 (pt) * 2003-09-19 2021-05-25 Janssen Pharmaceutica Nv ácidos 4-((fenoxialquila)tio)-fenoxiacéticos e análogos e composição farmacêutica compreendendo-os
US20070135382A1 (en) * 2003-10-22 2007-06-14 Phipps Richard P Use of peroxisome proliferator-activated receptor gamma (ppary) and/or retinoic acid receptor (rxr) agonists to inhibit platelet functions
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
US7402674B2 (en) 2004-01-31 2008-07-22 Sanofi-Aventis Deutschland Gmbh, 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7470706B2 (en) 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7498341B2 (en) 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
DE602004004631D1 (de) 2004-04-01 2007-03-22 Sanofi Aventis Deutschland Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
EP1647549A1 (de) 2004-10-14 2006-04-19 Laboratoire Theramex Indazole, Benzisoxazole und Benzisothiazole mit oestrogenen Eigenschaften
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
KR101419554B1 (ko) 2006-03-13 2014-07-17 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ­３ 억제제로서 아미노퀴놀론
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
BRPI0816798A2 (pt) 2007-09-11 2016-10-11 Activx Biosciences Inc composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
CN101855229A (zh) 2007-09-12 2010-10-06 埃迪威克斯生物科学公司 作为gsk-3抑制剂的螺环状氨基喹诺酮
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
BRPI1008974A2 (pt) 2009-03-11 2017-06-06 Kyorin Seiyaku Kk composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
AU2010232729A1 (en) 2009-03-31 2011-10-20 Arqule, Inc. Substituted indolo-pyridinone compounds
WO2011039338A2 (en) 2009-10-02 2011-04-07 Sanofi-Aventis Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CN104974103A (zh) * 2015-07-14 2015-10-14 佛山市赛维斯医药科技有限公司 一类含苯并异恶唑和烷氧苯基类结构的化合物及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200642A (en) 1978-08-21 1980-04-29 Pfizer Inc. Spiro-oxazolidindiones
AU6610081A (en) * 1980-01-24 1981-07-30 Senju Pharmaceutical Co., Ltd. Thiazolidine derivatives
US4367234A (en) 1980-07-28 1983-01-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4342771A (en) 1981-01-02 1982-08-03 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4332952A (en) 1980-07-28 1982-06-01 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4695634A (en) 1981-01-02 1987-09-22 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4689336A (en) 1981-01-02 1987-08-25 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine 2,4-diones
US4423233A (en) 1981-04-23 1983-12-27 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4430337A (en) 1982-06-23 1984-02-07 Pfizer Inc. Alicyclic substituted oxazolidine-2,4-diones having hypoglycemic activity
US5053420A (en) 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
GB9017218D0 (en) 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
JP3053490B2 (ja) * 1991-02-25 2000-06-19 杏林製薬株式会社 チアゾリジン−２，４−ジオン誘導体とその塩及び製造法
US5498621A (en) 1992-05-01 1996-03-12 Pfizer Inc. Oxazolidinedione hypoglycemic agents
TW268952B (de) 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
US5614544A (en) 1993-09-14 1997-03-25 Takeda Chemical Industries, Ltd. Oxazolidinedione derivatives and their use
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
TW403748B (en) 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
JPH0912575A (ja) 1995-06-28 1997-01-14 Sankyo Co Ltd ベンゾオキサジンおよびベンゾチアジン誘導体
JP3906935B2 (ja) * 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
CA2245524A1 (en) 1996-02-02 1997-08-07 Wei Han Antidiabetic agents
JP2002503202A (ja) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
ATE236137T1 (de) 1996-02-02 2003-04-15 Merck & Co Inc Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
CA2244831A1 (en) 1996-02-02 1997-08-07 John T. Olson Method of treating diabetes and related disease states
US5801173A (en) 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
RU2200161C2 (ru) * 1996-12-31 2003-03-10 Др. Редди'З Рисерч Фаундейшн Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение
EA200000687A1 (ru) * 1997-12-19 2000-12-25 Мерк Энд Ко., Инк. Производные арилтиазолидиндиона
US6008237A (en) 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives

Also Published As

Publication number Publication date
EP1194146A1 (de) 2002-04-10
US6399640B1 (en) 2002-06-04
ES2265952T3 (es) 2007-03-01
WO2000078312A1 (en) 2000-12-28
CA2376919A1 (en) 2000-12-28
DE60029446D1 (de) 2006-08-31
EP1194146B1 (de) 2006-07-19
AU773505B2 (en) 2004-05-27
DE60029446T2 (de) 2007-02-08
EP1194146A4 (de) 2002-07-31
AU5875500A (en) 2001-01-09
JP2003502369A (ja) 2003-01-21
CA2376919C (en) 2008-11-04

Similar Documents

Publication Publication Date Title
ATE333448T1 (de) Arylthiazolidinedione und aryloxa zolidinedion- derivate
ATE352545T1 (de) Arylthiazolidindion-derivate
AU7705601A (en) N-substituted indoles useful in the treatment of diabetes
WO2002026729A3 (en) Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
WO2002060434A3 (en) Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
WO2002064094A3 (en) 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
WO2002060388A3 (en) Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
NO20015607D0 (no) Glukagonantagonister/inversagonister
IS5194A (is) Notkun þíasólídíndíonafleiða við meðferð á fjölblöðrueggjastokkaheilkennum og þungunarsykursýki
ATE257703T1 (de) 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
DE60040293D1 (de) Verwendung von nikotin in der angiogenese und der vaskulogenese
NO20013469D0 (no) Fremgangsmåter for glukagonsuppresjon
DK0699192T3 (da) Substituerede oxazolylforbindelser til behandling af inflammation
MY134965A (en) Heterocyclic compounds and methods of use
DE60229922D1 (de) Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
MY119997A (en) Mesylate dihydrate salts of 5-(2-(4-(1, 2-benzisothiazol-3-yl) -1-piperazinyl)-6-chloro-1, 3- dihydro-2h-indol-2-one
WO2006014262A3 (en) Indoles having anti-diabetic activity
AU1653101A (en) Use of thiazole derivatives for treatment/prevention of p38 kinase mediated disorders
MXPA02004700A (es) Compuestos relacionados con acido 15-hidroxieicosatetraenoico y metodos de uso.
ECSP993022A (es) Derivados de ariltiazolidindiona
AR018898A1 (es) Derivados de 5-aril-2,4-tiazolidindiona, una composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de un medicamento
DOP2001000256A (es) Derivados del acidobenzopirancarboxilico para el tratamineto de la diabetes y los trastornos de lipidos.
ITMI930994A0 (it) Derivati del 2-(benzimidazol-2-il)-1,3-diaminopropano farmacologicamente

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties